SEC EDGARMAY 291 min read$CORT

Maduck Sean sold $4.9M of CORT

Maduck Sean (See Remarks) sold 75,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $65.59 ($65.37–$66.16, $4.92M total) across 2 trades on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Maduck Sean

Published May 29, 2026, 10:03 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 28, 2026, 3:47 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CORT

Bearish

medium confidence

Mentioned

$CORT

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CORTBearishLow

Why it matters

The disclosed sale adds supply and may prompt short sellers, but the impact is likely modest given the company's size.

Market read

Insider sale news is relevant for traders holding or shorting CORT; limited broader market effect.

What to watch

No immediate catalyst beyond the filing; the market may already price typical insider sales.

Relevance 5/10Novelty 4/10Timing: post‑market filing

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CORTBearishMedium confidence

Context

Officer Maduck Sean sold 75,000 shares for $4.9M via a 10b5‑1 plan, reducing his stake to 8,977 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $4.9M sale by an officer is material for a micro‑cap biotech and can trigger short‑term sell‑offs.

Market effects

Sector

May raise concerns for other small‑cap biotech insiders.

Regional

Limited to U.S. biotech investors.

Global

Minimal.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

Company
Corcept Therapeutics Inc
Biopharma listed on NASDAQ under CORT.
Officer
Maduck Sean
Insider officer executing a 10b5‑1 sale.

Read at source ← All news

SEP 22

$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min

SEP 19

$CORTHighAI 8/10

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

stocktwits.com2 min

SEP 18

$CORTMedAI 8/10

Corcept's Lifyorli Gets Positive EU Opinion For Platinum-Resistant Ovarian Cancer

Corcept Therapeutics (CORT) announced that the EMA's CHMP recommended approval of relacorilant for platinum-resistant ovarian cancer, based on Phase 2 and 3 trial data showing improved survival rates. The European Commission will decide by Q4 2026. CORT's stock closed at $114.86, up 2.73%, and was at $115.45 in premarket trading.

rttnews.com2 min

SEP 18

$CORTHighAI 9/10

Corcept Therapeutics Incorporated: Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant)

Corcept Therapeutics (CORT) announced the European Medicines Agency's CHMP recommended EU approval for relacorilant, combined with nab-paclitaxel, to treat platinum-resistant ovarian cancer. The recommendation follows positive Phase 2 and Phase 3 trial results showing improved survival rates. The EC will decide by Q4 2026. Relacorilant is already FDA-approved in the U.S. for the same indication.

finanznachrichten.de2 min

AUG 6

$CORTHighAI 9/10

Raised Guidance Lifts Corcept to 52-Week High

Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.

yahoo.com3 min

JUL 31

$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min